Artivion reported FY 2025 revenue of USD 441.33 million (+14%) and net income of USD 9.80 million. Gross margin was USD 284.23 million (64% of revenue), while general, administrative and marketing expenses rose to USD 226.49 million (+25%) and R&D expenses increased to USD 30.99 million (+9%). Interest expense fell to USD 26.60 million. By segment in FY 2025, product revenue was USD 345.83 million (+19%), led by aortic stent grafts at USD 159.37 million (+29%), On-X at USD 101.74 million (+21%), and surgical sealants at USD 76.60 million (+4%); preservation services revenue was USD 95.51 million (-3%). The company cited volume growth in aortic stent grafts and On-X, and noted limited impacts from its 2024 cybersecurity incident, including a tissue shipment backlog that it said was released in Q2 and Q3 2025 with shipments returning to normal levels. Artivion also highlighted U.S. AMDS sales following an FDA humanitarian device exemption granted in December 2024, and recorded a USD 7.00 million gain from sale of non-financial assets tied to PerClot sales milestones as part of the Baxter transaction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artivion Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-009046), on February 18, 2026, and is solely responsible for the information contained therein.